Pulmonary Diseases, Critical Care & Spring 2016 Volume 3, Issue 2 Environmental Medicine News In This Issue: Message from the Section Chief Message from the Section his issue of the Tulane Pulmonary/Critical Care News Letter Chief T largely focuses on regional and school educational efforts of the section. We offered two robustly attended community Dr. Ross Klingsberg Selected programs, specifically in pulmonary fibrosis and sarcoidosis this to Serve on the USMLE Acute past year, and look forward to facilitating more programs in the Care Test Material future. So please drop me an email with any suggestions on topics Development Committee that would be helpful for your practice ([email protected]). Tulane Multi-Specialty Joseph A. Lasky, MD Sarcoidosis CME Conference Professor of Medicine and Tulane/Foundation for Deming Educational Fund Chair of Internal Medicine Sarcoidosis Research (FSR) Chief, Section of Pulmonary Diseases, Critical Care & Patient Conference Environmental Medicine Available Pulmonary Clinical Trials Dr. Ross Klingsberg Selected to Serve on the USMLE® Acute Care Test Material Dr. Jay Shames receives Development Committee Outstanding Clinician Award from the Louisiana Thoracic Society and the American ulane Pulmonary Medicine physician-educator, Ross Thoracic Society T Klingsberg MD, has been selected to serve on the United States Medical Licensing Examination® (USMLE®) Acute Care NIH Awards Dr. Derek Pociask Test Material Development Committee. The USMLE® is R21 Research Grant sponsored by the National Board of Medical Examiners® (NBME®) and the Federation of State Medical Boards (FSMB). Dr. Fayez Kheir Receives AABIP Research Award The USMLE program conducts a periodic review of standards for each USMLE Step examination. Congratulations to Dr. Klingsberg Welcome Dr. Karin Halvorson for his selection to work on this important committee that helps set the national standards for medical licensure. His participation will Welcome Dr. Astha Chichra give our region representation on this important committee. He will also bring standardized test-writing skills back to Tulane to help Case Report improve our educational mission. Page 2 Pulmonary Diseases, Critical Care & Environmental Medicine News Tulane Multi-Specialty Sarcoidosis CME Conference and Tulane/Foundation for Sarcoidosis Research (FSR) Patient Conference aturday, February 27, 2016 held the first The feedback from patients and clinicians was S New Orleans Sarcoidosis Multi-Specialty very positive and comments were congratulato- and Patient conferences. It was a tremendous ry, for which we thank you, and are looking success on all counts. Of fifteen years of FSR forward to the next one. The invited interna- patient conferences, FSR proudly reports that tional conference faculty also report having a the New Orleans patient conference was 'out of wonderful stay and engagement with audiences the ball park!' with over 120 patient attendees - in New Orleans. With such strength of re- the largest Sarcoidosis Patient conference ever sponse, Tulane and the FSR are considering an held in the United States or elsewhere! annual New Orleans Patient conference and a bi-annual CME conference. Thanks to all for The CME Multi-Specialty Conference in Sar- making this inaugural event a magnificent suc- coidosis was the first CME conference dedicat- cess! ed to non-WASOG members providing high- level specialty specific and generalist Any comments or questions for the faculty ac- knowledge for clinicians with 122 registrants tivity director are welcomed by emailing Dr. (generalists, pulmonologists, cardiologists, neu- Lesley Ann Saketkoo, [email protected]. rologists and ophthalmologists as well as nurses and therapists). In addition to the medical spe- Tulane University, Center for Continuing Edu- cialty tract, a special session for pulmonary, cation has been accredited as an Accredited physical and occupational rehabilitationists was Provider by the International Association for also conducted. Continuing Education and Training (IACET). Tulane University, Center for Continuing Edu- We would like to thank our combined specialty cation is authorized by IACET to offer .8 CEUs moderating panels, that included regional and for this program or 7.75 AMA PRA Category 1 national experts and trainees, for the presenta- Credits ™. tion of highly educational and thought- provoking cases. Page 3 Fall 2015 Volume 3, Issue 1 Available Pulmonary Clinical Trials he following clinical trials are currently Cystic Fibrosis T available and enrolling patients. If your pa- VX15-371-101: A Phase 2a, Randomized, tient would like to be considered for any of these Double-blind, Placebo-controlled, Incom- trials, please contact the Pulmonary section: plete Block, Crossover Study to Evaluate the 504-988-4040 , 504-988-0743, or 504-988-2325 Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibro- Pulmonary Fibrosis sis, Homozygous for the F508del-CFTR Mu- Pulmonary Fibrosis Foundation Patient Reg- tation, and Being Treated With Orkambi. istry Protocol Novartis CTBM100C2407: A prospective A Phase 2, randomized, double-blind, place- Observational Study in cystic fibrosis pa- bo-controlled study of GBT440 to evaluate tients with chronic respiratory Pseudomonas the safety, tolerability, pharmacokinetics, and aeruginosa infection treated with TOBI® effect on hypoxemia in subjects with idio- Podhaler™ (tobramycin inhalation powder) pathic pulmonary fibrosis or other FDA approved inhaled antipseudo- monal antibacterial drugs A twelve week, open-label, randomized, par- allel-group study evaluating safety, tolerabil- Scleroderma and Sarcoidosis ity and pharmacokinetics(PK) of oral Acthar Gel for Chronic Pulmonary Sarcoido- nintedanib in combination with oral sis pirfenidone, compared to treatment with nin- (GRASP)-Genome Research in African tidanib alone, in patients with idiopathic pul- American Scleroderma Patients monary fibrosis. A double blind, randomized, placebo- Idiopathic Pulmonary Fibrosis Prospective controlled trial evaluating efficacy and safety Outcomes (IPF-PRO) Registry of oral nintedanib treatment for at least 52 Comparison of Transbronchial, Cryoprobe weeks in patients with Systemic Sclerosis and Vats Biopsy for the Diagnosis of Intersti- associated Interstitial Lung Disease (SSc- tial Lung Disease ILD) Pulmonary Hypertension Eosinophilic Disorders A Multicenter, Randomized, Double-Blinded, Human Eosinophilic Disorders in Health and Placebo-Controlled Trial to Evaluate the Disease Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease Page 4 Pulmonary Diseases, Critical Care & Environmental Medicine News Dr. Jay Shames receives Outstanding Clinician Award from the Louisiana Thoracic Society and the American Thoracic Society r. Jay Shames was honored by the Loui- Dr. Shames has served as a Clinical Professor at D siana Thoracic Society at the 60th An- Tulane University and Louisiana State Universi- nual Tri-State Case Conference in New Orleans ty. He has served in different very prominent on January 16th, 2016 with the Outstanding roles in the Orleans Parish Medical Society, Clinician Award recognizing a brilliant profes- Louisiana State Medical Society and American sional career that has greatly impacted our local Medical Association, societies that have also and regional community. Dr. Jay Shames was recognized his great work and have honored him also elected as the national Outstanding Clini- with several awards in the past. Dr. Shames is cian Awardee by the American Thoracic Socie- also one of the original founders of one of the ty; he will be receiving this recognition during most prestigious medical groups in the city of the international American Thoracic Society New Orleans, Internal Medicine Specialists, Inc. Meeting in May 2016 at San Francisco. In addition to the great impact in the health of Dr. Shames, originally from Iowa, received his his patients during his career, Dr. Shames has Medical Degree from Tulane University; he been a highly valued teacher and mentor to underwent an Internship at Jackson Memorial many medical students, residents and fellows. Hospital in Miami, followed by Internal Medi- He continues mentoring Tulane pulmonary fel- cine residency at Touro Infirmary and subse- lows during academic activities and outpatient quently a fellowship in Pulmonary Diseases at clinics, serving as one of their best role models Tulane University. During his medical career, for their future practice. Page 5 Fall 2015 Volume 3, Issue 1 NIH Awards Dr. Derek Dr. Fayez Kheir Receives Pociask R21 Research AABIP Research Award Grant r. Derek Pociask’s laboratory is focused r. Fayez Kheir was the recipient of the D on ways to improve the immune response D American Association of Bronchology during influenza infection and reduce the subse- and Interventional Pulmonology (AABIP) quent injury that occurs. A hallmark of severe research award (2016-2017) for his project influenza infection is thymic atrophy and associ- entitled “Silicone Airway Stents for Excessive ated peripheral lymphopenia. Given that lym- Dynamic Airway Collapse: A Randomized phopenia is strongly associated with secondary Placebo Controlled Double-Blinded Trial”. bacterial pneumonia, Adult Respiratory Distress He will carry on the project during his Inter- Syndrome (ARDS) and mortality, understanding ventional Pulmonology fellowship at Beth and targeting ways to promote thymic regenera- Israel Deaconess Medical Center